Ellen Leifer Shulman and Steven Shulman Digestive Disease Center, Cleveland Clinic Florida, Weston, Florida, USA.
Colorectal Surgery Unit, General Surgery Department, Mansoura University Hospitals, Mansoura, Egypt.
Colorectal Dis. 2024 Apr;26(4):622-631. doi: 10.1111/codi.16906. Epub 2024 Feb 15.
Colostomy complication rates range widely from 10% to 70%. The psychological burden on patients, leading to lifestyle changes and decreased quality of life (QoL), is one of the largest factors. The aim of this work was to assess the history and efficacy of ostomy continence devices in improving continence and QoL.
In this PRISMA-compliant systematic review and meta-analysis, we searched PubMed, Scopus, Google Scholar and clinicaltrials.gov for studies on continence devices for all ostomies up to April 2023. Primary outcomes were continence and improvement in QoL. Secondary outcomes were leakage, patient's device preference and complications. Risk of Bias 2 and the revised tool to assess risk of bias in non-randomized studies of interventions (ROBINS-1) were used to assess risk of bias. Certainty of evidence was graded using GRADE.
Twenty-two studies assessed devices from 1978 to 2022. The two main types identified were ball-valve devices and plug systems. Conseal and Vitala were the two main devices with significant evidence allowing for pooled analyses. Conseal, the only currently marketed device, had a pooled rate of continence of 67.4%, QoL improvement was 74.9%, patient preference over a traditional appliance was 69.1%, leakage was 10.1% and complications was 13.7%. Since 2011, five studies have investigated experimental devices on both human and animal models.
Ostomy continence has been a long-standing goal without a consistently reliable solution. We propose that selective and short-term usage of continence devices may lead to improved continence and QoL in ostomy patients. Further research is needed to develop a reliable daily device for ostomy continence. Future investigation should include the needs of ileostomates.
肠造口并发症的发生率范围很广,从 10%到 70%不等。患者的心理负担是导致生活方式改变和生活质量(QoL)下降的最大因素之一。本研究旨在评估造口术控便装置在改善控便和 QoL 方面的历史和疗效。
本研究遵循 PRISMA 原则,对截止至 2023 年 4 月的 PubMed、Scopus、Google Scholar 和 clinicaltrials.gov 进行了检索,以评估所有造口术的控便装置的研究。主要结局是控便和 QoL 的改善。次要结局是渗漏、患者对装置的偏好和并发症。采用风险偏倚 2 工具和修订的非随机干预研究风险偏倚评估工具(ROBINS-1)评估风险偏倚。使用 GRADE 对证据的确定性进行分级。
22 项研究评估了 1978 年至 2022 年期间的装置。确定的两种主要类型是球囊阀装置和塞栓系统。Conseal 和 Vitala 是两种具有重要证据的主要装置,允许进行汇总分析。目前唯一上市的 Conseal 装置的控便率为 67.4%,QoL 改善率为 74.9%,患者对传统器具的偏好率为 69.1%,渗漏率为 10.1%,并发症率为 13.7%。自 2011 年以来,有五项研究在人体和动物模型上研究了实验性装置。
肠造口术的控便一直是一个长期存在的目标,但没有一个始终可靠的解决方案。我们提出,选择性和短期使用控便装置可能会改善肠造口患者的控便和 QoL。需要进一步研究以开发一种可靠的肠造口术控便日常装置。未来的研究应包括回肠造口术患者的需求。